Inovalon (INOV) Issues FY 2018 Earnings Guidance

Inovalon (NASDAQ:INOV) issued an update on its FY 2018 earnings guidance on Wednesday morning. The company provided EPS guidance of $0.27-0.34 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.35. The company issued revenue guidance of $525-545 million, compared to the consensus revenue estimate of $570.11 million.Inovalon also updated its FY 2019 guidance to $0.41-0.47 EPS.

INOV stock traded down $0.09 during midday trading on Wednesday, reaching $10.08. 356,478 shares of the company traded hands, compared to its average volume of 525,747. Inovalon has a 52-week low of $8.90 and a 52-week high of $16.90. The company has a debt-to-equity ratio of 1.38, a current ratio of 1.95 and a quick ratio of 1.95. The company has a market cap of $1.43 billion, a PE ratio of 43.83, a price-to-earnings-growth ratio of 2.38 and a beta of 1.02.

INOV has been the topic of a number of recent research reports. BidaskClub upgraded Inovalon from a hold rating to a buy rating in a research report on Saturday, October 13th. ValuEngine downgraded Inovalon from a hold rating to a sell rating in a research report on Tuesday, September 4th. Finally, Zacks Investment Research upgraded Inovalon from a hold rating to a strong-buy rating and set a $14.00 price objective on the stock in a research report on Tuesday, August 7th. One investment analyst has rated the stock with a sell rating and four have issued a hold rating to the company. Inovalon has an average rating of Hold and a consensus target price of $11.67.

TRADEMARK VIOLATION NOTICE: “Inovalon (INOV) Issues FY 2018 Earnings Guidance” was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another site, it was stolen and republished in violation of US & international trademark and copyright law. The original version of this piece of content can be viewed at

Inovalon Company Profile

Inovalon Holdings, Inc, a technology company, provides cloud-based platforms empowering a data-driven transformation from volume-based to value-based models in the healthcare industry. The company's platform enables the assessment and enhancement of clinical and quality outcomes and financial performance.

Featured Article: What are the most popular ETFs

Receive News & Ratings for Inovalon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovalon and related companies with's FREE daily email newsletter.

Leave a Reply